Innovative ETFs Content Hub Small Caps Can Offer Investors Big Opportunities Through 2020 By Ben HernandezAugust 3, 2020
ETF Building Blocks Content Hub Betting on Biotech With Utility Beyond Covid-19 By Tom LydonJuly 31, 2020
Beyond Basic Beta Content Hub Big Biotech Stands Tall Amid Race for Virus Vaccine By Tom LydonJuly 17, 2020
Innovative ETFs Content Hub Get Next-Level Biotechnology Exposure with the “GDNA” ETF By Ben HernandezJuly 6, 2020
Thematic Investing Content Hub There’s Still Plenty of Opportunity for Biotech Post-Coronavirus By Tom LydonJune 16, 2020
Beyond Basic Beta Content Hub Biotech Benefits as Companies Race to Cure Coronavirus By Tom LydonMay 26, 2020
Leveraged & Inverse Content Hub Traders Can Look to Biotech ETFs to For a Potential Virus Cure By Ben HernandezMay 19, 2020
Beyond Basic Beta Content Hub How a Popular Biotech ETF Fits Into the Coronavirus Investing Landscape By Tom LydonMay 4, 2020
Beyond Basic Beta Content Hub Biotech ETFs Brush Off Political Attacks on Drug Prices By Tom LydonJanuary 21, 2020
ETF of the Week ETF of the Week: Virtus LifeSci Biotech Clinical Trials ETF (BBC) By Aaron NeuwirthDecember 12, 2019
Beyond Basic Beta Content Hub Biotech ETFs Could Use Some Mergers & Acquisitions By Tom LydonMay 17, 2019
Leveraged & Inverse Content Hub Big Biopharma Mergers Could Fuel These ETFs in 2019 By Ben HernandezJanuary 10, 2019
ETF of the Week ETF of the Week: Virtus LifeSci Biotech Clinical Trials ETF (BBC) By Brenton GarenSeptember 17, 2018
